Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Paclitaxel-Eluting vs. Sirolimus-Eluting Balloons

Coronary restenosis remains one of the main challenges in percutaneous transluminal coronary angioplasty (PTCA), especially nowadays, when procedures are increasingly complex and more stents are used, particularly in older patients.

Drug-eluting balloons (DEB) have proven to be beneficial in this scenario, according to several studies. Currently, there are paclitaxel- and sirolimus-eluting balloons, each with distinct characteristics. However, it is still unclear which of these drugs is superior or which circumstances would make one or the other more appropriate to use.

Researchers conducted a meta-analysis that included 1861 patients (from 5 randomized studies and 3 observational studies). Of these, 889 received paclitaxel-eluting balloons (PEB) and the rest received sirolimus-eluting balloons (SEB). Both de novo lesions and restenosis cases were included.

The assessment included clinical and angiographic events between 6 and 12 months of follow-up.

There were no significant differences between the groups in terms of the composite of cardiac death, myocardial infarction, or target vessel failure (odds ratio [OR] 1.01; 95% confidence interval [CI]: 0.75–1.35; I² = 0.0%). There were also no differences in cardiac mortality, myocardial infarction, or need for target lesion revascularization (TLR), which was consistent across both randomized and observational studies.

Read also: Plaque Morphology and Stent Elongation Assessed by OCT.

In the angiographic follow-up, patients who received PEB had a larger minimum luminal diameter compared to those who received SEB (0.10 mm, 95% CI: 0.02–0.17). This difference was more pronounced in de novo lesions than in restenosis cases.

Late lumen loss (the difference between the minimum luminal diameter during the procedure and at follow-up angiography) was also lower in patients treated with PEB compared with those who received SEB (-0.11 mm, 95% CI: -0.23 to 0.02; I² = 57.1%), although this difference was not statistically significant.

Conclusion:

At 9 and 12 months of follow-up, the rate of target lesion failure (TLF) was similar between the PEB and SEB groups. However, in the angiographic follow-up, the minimum luminal diameter was greater in patients who received PEB.

Original Title: Paclitaxel‐coated versus sirolimus‐coated balloon angioplasty for coronary artery disease: A systematic review and meta‐analysis.

Reference: Doosup Shin, et al. Catheter Cardiovasc Interv. 2024;104:425–436.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...